Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90.
Article
Google Scholar
Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8:1–20.
Article
CAS
Google Scholar
Majem M, Hernández-Hernández J, Hernando-Trancho F, Rodríguez de Dios N, Sotoca A, Trujillo-Reyes JC, et al. Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clin Transl Oncol. 2020;22:21–36.
Article
CAS
Google Scholar
Ozcelik M, Korkmaz T, Odabas H, Gemici C, Ercelep O, Yuksel S, et al. Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. Tumour Biol. 2016;37:8901–7.
Article
CAS
Google Scholar
Liew MS, Sia J, Starmans MH, Tafreshi A, Harris S, Feigen M, et al. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. Cancer Med. 2013;2:916–24.
Article
CAS
Google Scholar
Eberhardt WE. Concurrent chemoradiotherapy in stage III non-small-cell lung cancer: what is the best regimen? J Clin Oncol. 2015;33:532–3.
Article
CAS
Google Scholar
Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: randomized Phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34:953–62.
Article
CAS
Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–29.
Article
CAS
Google Scholar
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379:2342–50.
Article
CAS
Google Scholar
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354–62.
Article
CAS
Google Scholar
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–103.
Article
CAS
Google Scholar
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.
Article
CAS
Google Scholar
Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Ardine M, Barni S. Platinum rechallenge in patients with advanced NSCLC: a pooled analysis. Lung Cancer. 2013;81:337–42.
Article
Google Scholar
Sekine I, Shintani Y, Shukuya T, Takayama K, Inoue A, Okamoto I, et al. A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients. Cancer Sci. 2020;111:1685–91.
Article
CAS
Google Scholar
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.
Article
Google Scholar
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
Article
CAS
Google Scholar
Goto K, Ohe Y, Shibata T, Seto T, Takahashi T, Nakagawa K, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016;17:1147–57.
Article
CAS
Google Scholar
Ardizzoni A, Tiseo M, Boni L. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials. Eur J Cancer. 2014;50:2211–8.
Article
Google Scholar
Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771–5.
Article
Google Scholar
Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–106.
Article
CAS
Google Scholar
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–707.
Article
CAS
Google Scholar
Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F. Treatment of recurrent ovarian cancer. Ann Oncol. 2017;28:viii51–6.
Article
CAS
Google Scholar
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, et al. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02–2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol. 2012;30:4501–7.
Article
CAS
Google Scholar
Metro G, Chiari R, Mare M, Giannarelli D, Tofanetti FR, Minotti V, et al. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol. 2011;68:1405–12.
Article
CAS
Google Scholar
Yoh K, Kubota K, Kakinuma R, Ohmatsu H, Goto K, Niho S, et al. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy. Lung Cancer. 2007;58:73–9.
Article
Google Scholar
Arrieta O, Villarreal-Garza C, Pachuca D, Michel Ortega RM, Martinez-Barrera L, Flores-Estrada D, et al. High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy. Med Oncol. 2011;28:300–6.
Article
CAS
Google Scholar
Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N, et al. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer. 2010;10:633.
Article
CAS
Google Scholar
Kim HS, Lee GW, Kim JH, Kim HY, Kwon JH, Song HH, et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer. 2010;70:71–6.
Article
Google Scholar
Zhang GZ, Jiao SC, Meng ZT. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res. 2010;29:38.
Article
Google Scholar
Numico G, Colantonio I, Gasco M, Bertelli G, Garrone O, Occelli M, et al. Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy. Anticancer Res. 2005;25:2555–9.
CAS
PubMed
Google Scholar
Seto T, Takezako Y, Nakamura H, Takeda K, Inoue F, Semba H, et al. Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a phase II study. Int J Clin Oncol. 2004;9:378–82.
Article
CAS
Google Scholar
Stathopoulos GP, Rigatos S, Malamos NA. Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin. Oncol Rep. 1999;6:797–800.
CAS
PubMed
Google Scholar
Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Taira T, et al. Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy. Springerplus. 2015;4:152.
Article
Google Scholar
Horinouchi H, Atagi S, Oizumi S, Ohashi K, Kato T, Kozuki T, et al. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: the SOLUTION study. Cancer Med. 2020;9:6597–608.
Article
CAS
Google Scholar
Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92.
Article
CAS
Google Scholar
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–51.
Article
CAS
Google Scholar
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301.
Article
CAS
Google Scholar
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:924–37.
Article
CAS
Google Scholar
Reck M, Kaiser R, Mellemgaard A, Douillard J-Y, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143–55.
Article
CAS
Google Scholar
Garon EB, Ciuleanu T-E, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665–73.
Article
CAS
Google Scholar